Lypressin
Diapid (lypressin) is a protein pharmaceutical. Lypressin was first approved as Diapid on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lypressin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DIAPID | Novartis | N-016755 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
99 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 6 | — | 1 | 2 | 5 | 14 | ||
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 1 | 2 | 3 | 1 | 7 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | — | 2 | 2 | — | 5 |
| Psychotic disorders | D011618 | F20.81 | — | 1 | 1 | 2 | — | 4 | |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | — | 3 | — | 4 |
| Depression | D003863 | F33.9 | — | — | 1 | 2 | — | 3 | |
| Alcohol withdrawal delirium | D000430 | EFO_1000800 | — | — | — | 1 | 2 | 3 | |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | — | 1 | — | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | 1 | — | 2 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | — | 1 | — | 2 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Status epilepticus | D013226 | EFO_0008526 | G41 | 1 | 1 | 7 | — | 1 | 9 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | 1 | 2 | — | — | 4 |
| Seizures | D012640 | G40.4 | — | 1 | 4 | — | — | 4 | |
| Neoplasms | D009369 | C80 | — | 3 | 1 | — | — | 3 | |
| Dementia | D003704 | F03 | 1 | — | 1 | — | — | 2 | |
| Delirium | D003693 | R41.0 | — | 2 | 1 | — | — | 2 | |
| Psychophysiologic disorders | D011602 | F45.9 | — | — | 1 | — | — | 1 | |
| Vertigo | D014717 | H81.39 | — | — | 1 | — | — | 1 | |
| Critical illness | D016638 | — | 1 | 1 | — | — | 1 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | HP_0002013 | R11.1 | — | 1 | — | — | — | 1 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | 1 | — | — | — | 1 |
| Mania | D000087122 | F30 | — | 1 | — | — | — | 1 | |
| Acute pain | D059787 | R52 | — | 1 | — | — | — | 1 | |
| Analgesia | D000698 | — | 1 | — | — | — | 1 | ||
| Reflex epilepsy | D020195 | EFO_1001146 | — | 1 | — | — | — | 1 | |
| Cocaine-related disorders | D019970 | F14 | — | 1 | — | — | — | 1 | |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | 1 | — | — | — | 1 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | 1 | — | — | — | 1 |
| Psychology repression | D012094 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | 1 | 2 |
| Voice disorders | D014832 | 1 | — | — | — | — | 1 | ||
| Epidermolysis bullosa | D004820 | Q81 | 1 | — | — | — | — | 1 | |
| Neuroimaging | D059906 | 1 | — | — | — | — | 1 | ||
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | 1 | — | — | — | — | 1 |
| Catatonia | D002389 | F06.1 | 1 | — | — | — | — | 1 | |
| Nodding syndrome | D064128 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | — | 1 | 1 | |
| Genetic polymorphism | D011110 | — | — | — | — | 1 | 1 | ||
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | — | 1 | 1 |
| Alpha 1-antitrypsin deficiency | D019896 | E88.01 | — | — | — | — | 1 | 1 | |
| Argininosuccinic aciduria | D056807 | — | — | — | — | 1 | 1 | ||
| Cognition | D003071 | EFO_0003925 | — | — | — | — | 1 | 1 | |
| Benign paroxysmal positional vertigo | D065635 | — | — | — | — | 1 | 1 | ||
| Infertility | D007246 | EFO_0000545 | — | — | — | — | 1 | 1 | |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | — | 1 | 1 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LYPRESSIN |
| INN | lypressin |
| Description | Argipressin is the predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. It has a role as a cardiovascular drug, a hematologic agent and a mitogen. It is a conjugate base of an argipressin(2+). |
| Classification | Protein |
| Drug class | vasoconstrictors (vasopressin derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O |
Identifiers
| PDB | — |
| CAS-ID | 50-57-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200690 |
| ChEBI ID | — |
| PubChem CID | 644077 |
| DrugBank | DB00067 |
| UNII ID | 7CZF3L922Y (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 176 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
33,924 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more